Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global company in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. This news page aggregates announcements, press releases, and corporate updates related to Waters, giving readers a focused view of developments that affect the company and its markets.
Investors and industry professionals can use this feed to follow Waters’ product launches, financial results, and strategic initiatives. Recent news has highlighted new technologies such as the Xevo Charge Detection Mass Spectrometer (CDMS), which Waters describes as enabling direct mass detection for large biomolecules relevant to next-generation therapeutics, and a Charged Aerosol Detector designed for use with the company’s Empower chromatography data system. These announcements illustrate how Waters is addressing analytical challenges in pharmaceuticals, biotherapeutics, food analysis, and environmental testing.
The news stream also features quarterly earnings releases, where Waters reports sales performance, instrument and recurring revenue trends, and commentary from management. In addition, Waters issues updates on investor conference presentations and on the planned combination with BD’s Biosciences & Diagnostic Solutions business via a Reverse Morris Trust transaction, as described in its press releases and Form 8-K filings.
By reviewing Waters-related news in one place, readers can track themes such as instrument replacement cycles, adoption of new chromatography and mass spectrometry products, and the company’s expansion into adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. Bookmark this page to monitor ongoing disclosures and media releases that shape the narrative around WAT stock and Waters’ role in regulated, high-volume testing and scientific markets.
Waters Corporation (NYSE:WAT) has expanded its collaboration with Singapore's Bioprocessing Technology Institute (BTI) to enhance analytics in glycomics and metabolomics. The partnership aims to improve the rapid identification of complex biomolecules that are crucial for biologics manufacturing. Utilizing advanced instruments like the SYNAPT™ mass spectrometry system, the project addresses the challenges of characterizing biopharmaceuticals through data analytics and machine learning. This collaboration builds on a successful relationship since 2014, targeting cost reduction and efficiency in biomanufacturing processes.
Waters Corporation (NYSE: WAT) has appointed Wei Jiang to its Board of Directors, effective July 14, 2021. Wei currently serves as Executive Vice President at Bayer Pharmaceuticals for the China and APAC regions. His expertise in driving results in fast-growing markets, particularly in China, is viewed as a significant asset for Waters. Dr. Udit Batra, CEO, notes that Wei's experience aligns with the company's growth strategy in the pharmaceutical sector. Wei expressed enthusiasm about contributing to Waters' ongoing transformation, highlighting growth potential in China's pharma market.
Waters Corporation (NYSE:WAT) has launched the Waters Arc Premier System, the first liquid chromatography system designed for 2.5 – 3.5 micron columns featuring MaxPeak High Performance Surface (HPS) technology. This system reduces analyte-surface interactions, thereby improving analytical results for laboratories. Benefits include increased sensitivity, reproducibility, and potential savings of 2-3 days per assay by eliminating passivation. The combination of the Arc Premier System and MaxPeak Premier Columns aims to enhance productivity, accuracy, and confidence in pharmaceutical analysis.
Waters Corporation (NYSE:WAT) has launched the Waters™ SELECT SERIES™ MRT, an advanced mass spectrometer integrating Multi Reflecting Time-of-Flight (MRT) technology with enhanced DESI and new MALDI imaging sources. This device allows for rapid, precise identification of molecules, achieving speeds of up to 10Hz without losing mass accuracy. The SELECT SERIES MRT boasts a resolution of 200,000 FWHM, setting a new standard in mass spectrometry. Shipments are slated to begin in Q4 of this year, promising significant advancements in biological research and imaging applications.
Waters Corporation (NYSE:WAT) has launched a new RUO LC-MS test method, the SARS-CoV-2 LC-MS Kit, to enhance infectious disease research. This innovative method allows for the direct detection and quantification of SARS-CoV-2 Nucleocapsid (NCAP) peptides, yielding highly accurate results. Developed in collaboration with various research entities, this method aims to support high-throughput screening with reduced reliance on PCR reagents. The kit can quantify low levels of NCAP peptides, facilitating impactful studies on infection stages and future pandemic preparedness.
Summary not available.
Waters Corporation (NYSE: WAT) reported first quarter 2021 sales of $609 million, up 31% from $465 million in Q1 2020. EPS rose to $2.37 (GAAP) from $0.86 yoy. Net cash from operations reached $218 million, an increase from $152 million. Instrument sales grew 49%, with pharmaceutical sales up 32%. The company anticipates full-year 2021 constant-currency sales growth of 8% to 11% and non-GAAP EPS of $9.85 to $10.05. The Q1 earnings call is scheduled for May 5, 2021.
Waters Corporation (NYSE:WAT) will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 12, 2021, at 2:00 PM EST. CEO Udit Batra will address the investment community, discussing the company’s innovations in chromatography and mass spectrometry that have served the life sciences for over 60 years. Waters, a leader in specialty measurement, has a global workforce of 7,400 and operates in 35 countries.
Waters Corporation (NYSE: WAT) announced significant leadership changes as part of its transformation program. Amol Chaubal will become the new CFO on May 12, 2021, bringing extensive financial experience from Quanterix Corporation. Michael Silveira resumes his role as Corporate Controller. Retirements for Dr. Mike Harrington and Ian King will take effect on July 2, 2021. The company has established an Innovation Board to enhance R&D collaboration. Jonathan Pratt and Jianqing Bennett have been appointed in key positions, aiming to drive growth and innovation.
Waters Corporation (NYSE:WAT) and Genovis AB are partnering to create automated biopharmaceutical characterization workflows using Waters' BioAccord LC-MS System, Andrew+ pipetting robot, and Genovis' SmartEnzymes. This collaboration aims to improve the speed and consistency of analytical processes involving monoclonal antibodies and protein-based drugs. By integrating automation and advanced enzyme technology, they target enhancements in quality control and bioprocess development, addressing significant bottlenecks in current biologics analysis.